DONALD BERRY to Adult
This is a "connection" page, showing publications DONALD BERRY has written about Adult.
Connection Strength
0.562
-
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. PLoS One. 2021; 16(7):e0255228.
Score: 0.032
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
Score: 0.030
-
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017 Jul 13; 3(7):e170580.
Score: 0.024
-
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36.
Score: 0.019
-
ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9.
Score: 0.019
-
Breast cancer screening: controversy of impact. Breast. 2013 Aug; 22 Suppl 2:S73-6.
Score: 0.018
-
Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012 Aug; 164(2):138-45.
Score: 0.017
-
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3224-31.
Score: 0.016
-
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3214-23.
Score: 0.016
-
Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst. 2007 Aug 01; 99(15):1139-41.
Score: 0.012
-
Strategies to improve healthcare websites. AMIA Annu Symp Proc. 2006; 969.
Score: 0.011
-
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 Oct 27; 353(17):1784-92.
Score: 0.011
-
Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA. 2024 01 16; 331(3):233-241.
Score: 0.009
-
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.
Score: 0.008
-
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
Score: 0.008
-
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
Score: 0.008
-
Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial. Neurocrit Care. 2022 04; 36(2):560-572.
Score: 0.008
-
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308.
Score: 0.008
-
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
Score: 0.008
-
Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clin Cancer Res. 2021 02 15; 27(4):1174-1183.
Score: 0.008
-
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.
Score: 0.008
-
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PLoS One. 2020; 15(8):e0237693.
Score: 0.007
-
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069.
Score: 0.007
-
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1360-1369.
Score: 0.007
-
Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1998 Oct 07; 90(19):1431-9.
Score: 0.007
-
Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998 Oct-Dec; 18(4):365-75.
Score: 0.007
-
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219.
Score: 0.006
-
Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
Score: 0.006
-
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 05; 89(3):227-38.
Score: 0.006
-
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). J Am Coll Surg. 2017 Apr; 224(4):688-694.
Score: 0.006
-
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.
Score: 0.006
-
Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials. 2016 07 29; 17:373.
Score: 0.006
-
Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22.
Score: 0.006
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
Score: 0.006
-
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med. 2016 Feb 16; 164(4):215-25.
Score: 0.005
-
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20; 34(6):542-9.
Score: 0.005
-
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015 Sep; 262(3):434-9; discussion 438-9.
Score: 0.005
-
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9).
Score: 0.005
-
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7.
Score: 0.005
-
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014 Nov; 106(11).
Score: 0.005
-
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 01; 33(1):13-21.
Score: 0.005
-
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014 Jun; 106(6):dju092.
Score: 0.005
-
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43.
Score: 0.004
-
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012 Sep; 158(5):581-8.
Score: 0.004
-
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
Score: 0.004
-
Modeling the impact of population screening on breast cancer mortality in the United States. Breast. 2011 Oct; 20 Suppl 3:S75-81.
Score: 0.004
-
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9.
Score: 0.004
-
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8.
Score: 0.004
-
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302.
Score: 0.004
-
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16; 102(4):651-7.
Score: 0.004
-
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8.
Score: 0.004
-
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13.
Score: 0.004
-
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009 Nov 17; 151(10):738-47.
Score: 0.004
-
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
Score: 0.004
-
Re: Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1999 Feb 17; 91(4):382-4.
Score: 0.003
-
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008 Jul 10; 26(20):3338-45.
Score: 0.003
-
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65.
Score: 0.003
-
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1096-103.
Score: 0.003
-
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90.
Score: 0.003
-
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
Score: 0.003
-
Limited family structure and breast cancer risk. JAMA. 2007 Nov 07; 298(17):2007; author reply 2007-8.
Score: 0.003
-
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
Score: 0.003
-
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 02; 147(7):441-50.
Score: 0.003
-
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol. 2007 May; 2(5):397-401.
Score: 0.003
-
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8.
Score: 0.003
-
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006 Feb 20; 24(6):863-71.
Score: 0.003
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.003
-
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
Score: 0.002
-
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8.
Score: 0.002
-
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9.
Score: 0.002
-
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003 May 01; 21(9):1825-35.
Score: 0.002
-
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
Score: 0.002
-
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
Score: 0.002
-
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res. 2002 Mar; 8(3):698-705.
Score: 0.002
-
Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105.
Score: 0.002
-
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001 Sep; 7(9):2703-11.
Score: 0.002
-
Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplant. 2001 Jun; 27(12):1245-53.
Score: 0.002
-
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001 Mar 15; 19(6):1698-706.
Score: 0.002
-
Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000 Feb; 18(3):600-8.
Score: 0.002
-
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct; 17(10):3064-74.
Score: 0.002
-
Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol. 1999 Aug; 74(2):208-16.
Score: 0.002
-
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
Score: 0.002
-
Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73.
Score: 0.002
-
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6.
Score: 0.002
-
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol. 1999 Jan; 17(1):64-73.
Score: 0.002
-
Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1998 Dec 02; 90(23):1824-9.
Score: 0.002
-
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16; 90(18):1346-60.
Score: 0.002
-
Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84.
Score: 0.002
-
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998 Mar; 16(3):1008-12.
Score: 0.002
-
Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998 Jan; 21(2):117-22.
Score: 0.002
-
The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant. 1997 Jun; 3(2):91-7.
Score: 0.001
-
Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res. 1997 May; 3(5):661-7.
Score: 0.001
-
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol. 1996; 37(6):561-8.
Score: 0.001
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
Score: 0.001
-
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat. 1995; 36(1):35-40.
Score: 0.001
-
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 05; 330(18):1260-6.
Score: 0.001
-
Bounded limits and statistical inference in chronobiometry. Prog Clin Biol Res. 1990; 341B:417-28.
Score: 0.001
-
Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate. Clin Pharmacol Ther. 1989 Jul; 46(1):1-8.
Score: 0.001
-
The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin Pharmacol Ther. 1989 Jul; 46(1):26-32.
Score: 0.001
-
Variability of different methods for measurement of ECG intervals and ECG interval temporal variation. J Electrocardiol. 1989; 22 Suppl:125-6.
Score: 0.001
-
A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study. Cancer. 1989 Jan 01; 63(1):23-9.
Score: 0.001
-
The pharmacodynamic and pharmacokinetic interaction of flecainide acetate with propranolol: effects on cardiac function and drug clearance. Eur J Clin Pharmacol. 1987; 33(1):97-9.
Score: 0.001
-
Application of second-order polynomial equations to the study of pharmacodynamic interactions: the effect of flecainide acetate and propranolol on cardiac output and vascular resistance. J Pharmacol Exp Ther. 1984 Nov; 231(2):286-90.
Score: 0.001